PL365283A1 - Nowy sposób syntezy fenyloamidu kwasu 5-(4-fluorofenylo)-1-[2-((2R,4R)-4-hydroksy-6-oksotetrahydropiran-2-ylo) etylo]-2-izopropylo-4-fenylo-1H-pirolo-3-karboksylowego - Google Patents

Nowy sposób syntezy fenyloamidu kwasu 5-(4-fluorofenylo)-1-[2-((2R,4R)-4-hydroksy-6-oksotetrahydropiran-2-ylo) etylo]-2-izopropylo-4-fenylo-1H-pirolo-3-karboksylowego

Info

Publication number
PL365283A1
PL365283A1 PL01365283A PL36528301A PL365283A1 PL 365283 A1 PL365283 A1 PL 365283A1 PL 01365283 A PL01365283 A PL 01365283A PL 36528301 A PL36528301 A PL 36528301A PL 365283 A1 PL365283 A1 PL 365283A1
Authority
PL
Poland
Prior art keywords
pyran
fluorophenyl
tetrahydro
oxo
isopropyl
Prior art date
Application number
PL01365283A
Other languages
English (en)
Inventor
Donald Eugene Butler
Randall Lee Dejong
Jade Douglas Nelson
Michael Gerard Pamment
Timothy Lee Stuk
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of PL365283A1 publication Critical patent/PL365283A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Catalysts (AREA)
PL01365283A 2001-01-09 2001-12-27 Nowy sposób syntezy fenyloamidu kwasu 5-(4-fluorofenylo)-1-[2-((2R,4R)-4-hydroksy-6-oksotetrahydropiran-2-ylo) etylo]-2-izopropylo-4-fenylo-1H-pirolo-3-karboksylowego PL365283A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26050501P 2001-01-09 2001-01-09
PCT/IB2001/002729 WO2002055519A2 (en) 2001-01-09 2001-12-27 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide

Publications (1)

Publication Number Publication Date
PL365283A1 true PL365283A1 (pl) 2004-12-27

Family

ID=22989433

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365283A PL365283A1 (pl) 2001-01-09 2001-12-27 Nowy sposób syntezy fenyloamidu kwasu 5-(4-fluorofenylo)-1-[2-((2R,4R)-4-hydroksy-6-oksotetrahydropiran-2-ylo) etylo]-2-izopropylo-4-fenylo-1H-pirolo-3-karboksylowego

Country Status (24)

Country Link
US (7) US6476235B2 (pl)
EP (1) EP1353917B1 (pl)
JP (2) JP4190285B2 (pl)
KR (3) KR100833911B1 (pl)
CN (4) CN101024626A (pl)
AR (1) AR035680A1 (pl)
AT (1) ATE358126T1 (pl)
BR (1) BR0116739A (pl)
CA (1) CA2432064C (pl)
CY (1) CY1106590T1 (pl)
CZ (1) CZ20031893A3 (pl)
DE (1) DE60127583T2 (pl)
DK (1) DK1353917T3 (pl)
ES (1) ES2282200T3 (pl)
HU (1) HUP0302647A3 (pl)
IL (4) IL156461A0 (pl)
MX (1) MXPA03005284A (pl)
PL (1) PL365283A1 (pl)
PT (1) PT1353917E (pl)
RU (1) RU2244714C1 (pl)
TW (1) TWI293073B (pl)
WO (1) WO2002055519A2 (pl)
YU (1) YU49003A (pl)
ZA (1) ZA200304684B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
MXPA03012045A (es) * 2001-07-06 2004-03-29 Teva Pharma Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN100357289C (zh) 2002-08-06 2007-12-26 沃尼尔·朗伯有限责任公司 制备5－(4－氟苯基)－1－[2－((2r,4r)－4－羟基－6－氧代－四氢－吡喃－2－基)乙基]－2－异丙基－4－苯基－1h－吡咯－3－羧酸苯基酰胺的方法
KR100765555B1 (ko) * 2002-08-06 2007-10-09 워너-램버트 캄파니 엘엘씨 5-(4-플루오로페닐)-1-[2-((2ｒ,4ｒ)-4-히드록시-6-옥소-테트라히드로-피란-2-일)에틸]-2-이소프로필-4-페닐-1ｈ-피롤-3-카르복실산 페닐아미드의 제조 방법
AU2003295684A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries Ltd. Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
EP1615883A1 (en) * 2003-04-14 2006-01-18 Warner-Lambert Company Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US7166638B2 (en) * 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7396947B2 (en) * 2003-06-13 2008-07-08 Lanxess Deutschland Gmbh Chiral ligands for application in asymmetric syntheses
CN101318923A (zh) * 2003-09-17 2008-12-10 沃尼尔·朗伯有限责任公司 [R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
CN1871202A (zh) 2003-10-24 2006-11-29 隆萨股份公司 6,6,6－三卤－3,5－二氧代己酸酯的制备方法
US20050152323A1 (en) * 2004-01-12 2005-07-14 Vincent Bonnassieux Plug-in Wi-Fi access point device and system
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
CN1960972A (zh) * 2004-04-16 2007-05-09 辉瑞产品公司 用于形成无定形阿托伐它汀钙的方法
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CZ299175B6 (cs) * 2004-06-17 2008-05-07 Zentiva, A. S Zpusob stanovení enantiomerní cistoty 2-(4-fluorfenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-fenyl-4[(fenylamino)-karbonyl]-1H-pyrrol-1-heptanové kyseliny a jejích solí
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
CA2573426C (en) * 2004-07-30 2015-11-17 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
WO2006046109A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
WO2006067795A2 (en) * 2004-12-23 2006-06-29 Jubilant Organosys Limited Novel polymorphic forms of atorvastatin lactone and process for preparing the same
WO2006097909A1 (en) * 2005-03-14 2006-09-21 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate using a paal-knorr condensation
EP1705175A1 (en) * 2005-03-24 2006-09-27 ratiopharm GmbH Process for preparing C5 products and their use for Atorvastatin synthesis
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
GB0523637D0 (en) * 2005-11-21 2005-12-28 Avecia Pharmaceuticals Ltd Process and compounds
CA2652412A1 (en) * 2006-05-15 2007-11-22 Ratiopharm Gmbh Process for preparing c5 intermediates and their use in the preparation of n-substituted pyrrole derivatives
KR101069698B1 (ko) * 2008-08-28 2011-10-04 한국화학연구원 광학 활성을 갖는 (4ｒ, 6ｒ)-6-(2-아미노에틸)-4-하이드록시-테트라하이드로피란-2-온 유도체의 제조방법
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2373609B1 (en) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2473515A4 (en) 2009-09-04 2013-11-27 Univ Toledo PROCESS FOR PREPARING OPTICALLY PURE BETA LACTONS FROM ALDEHYDE AND COMPOSITIONS MADE THEREOF
KR100986755B1 (ko) * 2009-12-29 2010-10-08 김우진 노즐 회전장치 및 이를 갖는 분수
CN101892276B (zh) * 2010-06-12 2012-11-21 郝志艳 一种阿托伐他汀钙化合物及其新方法
EP2616454B1 (en) 2010-09-16 2015-04-15 DSM Sinochem Pharmaceuticals Netherlands B.V. Esters of hexanoic acids as intermediates for the preparation of atorvastatin
BRPI1101952B1 (pt) * 2011-04-25 2022-02-01 Universidade Estadual De Campinas - Unicamp Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida
US20140335179A1 (en) 2011-07-01 2014-11-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
US20190038588A1 (en) * 2016-02-11 2019-02-07 Stichting Katholieke Universiteit Novel class of compounds for the treatment of cardiovascular disease
EP3710422B1 (en) * 2017-11-16 2026-01-07 Syngenta Crop Protection AG Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides
US11513815B1 (en) 2019-05-24 2022-11-29 Hiro Systems Pbc Defining data storage within smart contracts
US10699269B1 (en) * 2019-05-24 2020-06-30 Blockstack Pbc System and method for smart contract publishing
US11657391B1 (en) 2019-05-24 2023-05-23 Hiro Systems Pbc System and method for invoking smart contracts
CN113559318B (zh) * 2021-07-05 2022-09-13 四川大学 一种促神经功能恢复的手性导电修复支架及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
GEP20002029B (en) 1995-07-17 2000-04-10 Warner Lambert Company Us (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO1997037985A1 (en) * 1996-04-10 1997-10-16 Warner-Lambert Company Nonpeptide endothelin antagonists with increased water solubility
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
TR199900191T2 (xx) 1996-07-29 1999-04-21 Warner-Lambert Company (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Also Published As

Publication number Publication date
DK1353917T3 (da) 2007-06-18
KR20060015698A (ko) 2006-02-17
CN1222521C (zh) 2005-10-12
AU2002222430B2 (en) 2007-05-17
KR100677008B1 (ko) 2007-02-01
US6545153B1 (en) 2003-04-08
US20020133026A1 (en) 2002-09-19
KR100833911B1 (ko) 2008-06-03
JP2008100989A (ja) 2008-05-01
RU2244714C1 (ru) 2005-01-20
TWI293073B (en) 2008-02-01
KR20030065594A (ko) 2003-08-06
JP2004520351A (ja) 2004-07-08
EP1353917A2 (en) 2003-10-22
US7399773B2 (en) 2008-07-15
MXPA03005284A (es) 2003-09-25
US7371855B2 (en) 2008-05-13
IL189357A0 (en) 2008-06-05
IL189359A0 (en) 2008-06-05
ZA200304684B (en) 2004-06-28
CZ20031893A3 (cs) 2004-03-17
US20070032662A1 (en) 2007-02-08
AR035680A1 (es) 2004-06-23
US7361771B2 (en) 2008-04-22
CN1907984A (zh) 2007-02-07
EP1353917B1 (en) 2007-03-28
DE60127583D1 (de) 2007-05-10
HK1060572A1 (en) 2004-08-13
US6476235B2 (en) 2002-11-05
IL189358A0 (en) 2008-06-05
YU49003A (sh) 2006-05-25
US20070032664A1 (en) 2007-02-08
ES2282200T3 (es) 2007-10-16
US20070032663A1 (en) 2007-02-08
KR100582326B1 (ko) 2006-05-22
CN101024626A (zh) 2007-08-29
US6933393B2 (en) 2005-08-23
CN100351252C (zh) 2007-11-28
CA2432064C (en) 2007-09-11
HUP0302647A3 (en) 2009-03-30
WO2002055519A3 (en) 2002-09-19
HUP0302647A2 (hu) 2003-11-28
HK1084114A1 (zh) 2006-07-21
DE60127583T2 (de) 2007-12-06
ATE358126T1 (de) 2007-04-15
PT1353917E (pt) 2007-05-31
US7183408B2 (en) 2007-02-27
US20050239869A1 (en) 2005-10-27
KR20060114395A (ko) 2006-11-06
CN1696129A (zh) 2005-11-16
US20030195353A1 (en) 2003-10-16
BR0116739A (pt) 2003-09-30
CN1489587A (zh) 2004-04-14
JP4190285B2 (ja) 2008-12-03
IL156461A0 (en) 2004-01-04
CY1106590T1 (el) 2012-01-25
CA2432064A1 (en) 2002-07-18
WO2002055519A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
PL365283A1 (pl) Nowy sposób syntezy fenyloamidu kwasu 5-(4-fluorofenylo)-1-[2-((2R,4R)-4-hydroksy-6-oksotetrahydropiran-2-ylo) etylo]-2-izopropylo-4-fenylo-1H-pirolo-3-karboksylowego
IL157478A0 (en) Method for the synthesis of 2', 3'-didehydronucleosides
AP2003002836A0 (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors.
MXPA03006322A (es) Procedimiento mejorado para la sintesis de carbapenem.
MXPA03008205A (es) Procedimiento para la preparacion de compuestos de imidazol.
PL375415A1 (pl) Sposób wytwarzania fenyloamidu kwasu 5-(4-fluorofenylo)-1-[2-((2R,4R)-4-hydroksy-6-okso-tetrahydropiran-2-ylo)-etylo]-2-izopropylo-4-fenylo-1H-pirolo-3-karboksylowego
IL149974A0 (en) Process for the preparation of 5-(1-piperazinyl) benzofuran-2-carboxamide by transition metal-catalysed amination
AU2001237752A1 (en) An improved process for preparing simvastatin
MXPA02006102A (es) Metodo para preparar compuestos bormodifluoroaceticos.
ZA200309542B (en) Process for determining the biomechanical compatibility of head equipment.
AU2003222435A8 (en) Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
PL368320A1 (pl) Sposób wytwarzania 5-podstawionych izobenzofuranów
HUP0303969A3 (en) Method for producing 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane
HRP20040557A2 (en) Process for preparing 2-(substituted phenyl)-2-hydroxy carbamates
WO2004089894A8 (en) Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
AP2005003229A0 (en) Process for preparing of paclitaxel.
PL372984A1 (pl) Nowe pochodne 3-(4-okso-4H-chromen-2-yl)-(1H)-chinolin-4-onu, sposób ich otrzymywania i zawierająceje kompozycje farmaceutyczne
ITTO20010934A0 (it) Macchina per la composizione di tappi incollati.
AU2002361068A1 (en) Process for the preparation of 3-(2-(3,4-dimethoxy-benzoyl)-4,5-dimethoxy-phenyl)-pentan-2-one
IL157101A0 (en) Method for preparing compounds derived from thiazolidinedione, oxazolidinedione or hydantoin
HUP0001127A3 (en) Process for producing n-[5-(diphenyl-phosphinoyl-methyl)-4-(4-fluorphenyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethan sulfonamid
GB2385051B (en) Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
HUP0401439A3 (en) Method for synthesis of 5-(3-pyridylmethylene)-imidazolidine-2,4-dione
PL376098A1 (pl) Sposób wytwarzania 3,3a,6,6a-tetrahydro-2H-cyklopentano[b]furan-2-onu
AU2002344437A1 (en) Process for producing 5-substituted 2(5h)-furanone

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)